Owlstone
Non-invasive Screening Device for Early Stage Lung Cancer
- Funding £1,094,772
- Competition Cancer
- Competition Date Autumn 2014
- Local AHSN Eastern AHSN
- Website http://www.owlstonenanotech.com/
- Key Contact Billy Boyle
- Status On Market
- Pathways CancerPathways Respiratory
-
Technology Medical Devices
Owlstone is developing a non-invasive screening device for early stage lung cancer utilizing breath diagnostics. As for most cancers, early diagnosis of lung cancer leads to better patient outcomes. The LuCID (Lung Cancer Indicator Detection) project will allow Owlstone’s existing chemical detection technology to be used to diagnose lung cancer, by measuring the trace chemicals present in the breath of lung cancer patients.
Comments are closed.